| Literature DB >> 25808146 |
Bi Li1, Wenqiang Yan2, Chenze Zhang3, Yuzhong Zhang4, Miao Liang5, Fuhao Chu6, Yan Gong7, Bing Xu8, Penglong Wang9, Haimin Lei10.
Abstract
There has been no remarkable progress in the synthesis of sultones in recent years. To facilitate more detailed studies of this functional group, we found a new method to synthesize the sulfonic acid lactone derivatives and finish its ring-closing reaction. A new sultone derivative, (E)-ethyl 4-oxo-6-styryl-3,4-dihydro-1,2-oxathiine-5-carboxylate 2,2-dioxide (S-CA), was synthesized and structurally identified by 1H-NMR, 13C-NMR, HMQC and X-ray single crystal diffraction analysis. The new rapid synthesis extended the method of ring-closing reaction of sulfonic acid lactone derivatives. The angiogenesis activities of S-CA were evaluated by the chick chorioallantoic membrane (CAM) model. It could selectively suppress small angiogenesis in CAM, without influencing either middle and large angiogenesis. In addition, anticancer efficacy of S-CA was evaluated in vivo using a murine sarcoma S180 model. Reduction of the tumor weight and tumor HE staining regions demonstrated that S-CA (10 mg/kg, intraperitoneal injection) had potent inhibition effects and a 44.71% inhibitory rate in S180 mice. Moreover, an acute toxicity test showed that the LD50 value of S-CA via intraperitoneal injection was 25.624 mg/kg.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25808146 PMCID: PMC6272555 DOI: 10.3390/molecules20034307
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1The synthetic route to S-CA.
Figure 1Crystal structure of S-CA.
Crystallographic data and structure refinement summary for S-CA.
| Phase | Compound |
|---|---|
| Molecular formula | C15 H14 O6 S |
| Formula weight | 322.32 |
| T/K | 296(2) K |
| Wavelength/nm | 0.71073 |
| Crystal system | Triclinic |
| Space group | P-1 |
| a/Å | 8.5023(2) |
| b/Å | 9.1314(2) |
| c/Å | 10.6477(2) |
| α (°) | 71.512(2) |
| β (°) | 83.356(2) |
| γ (°) | 72.179(2) |
| V (Å3) | 746.22(3) |
| Z | 2 |
| F(000) | 336 |
| Dcalc (mg/m3) | 1.434 |
| Absorption coefficient (mm−1) | 0.243 |
| θ range/(°) | 2.02–27.59 |
| Limiting indices | −10 ≤ h ≤ 11, −11 ≤ k ≤ 11, −13 ≤ l ≤ 13 |
| Reflections collected/unique | 7340/3419 [R(int) = 0.0197] |
| Completeness to theta | 99.0% |
| Data/restraints/parameters | 3419/0/199 |
| Refinement method | Full-matrix least-squares on F2 |
| Final R indices[I > 2σ(I)] | R1 = 0.0513, wR2 = 0.1377 |
| R indices (all data) | R1 = 0.0822, wR2 = 0.1586 |
| Goodness-of-fit on F2 | 1.055 |
| Largest diff. peak and hole/(e·Å ×10−3) | 0.656 and −0.215 |
| CCDC | 1052338 |
Figure 2Microvascular proliferation of S-CA on CAM (×50). (a) Blank control for S-CA group, (b) Positive control for S-CA group, (c) 10 μg/egg for S-CA group, (d) 40 μg/egg for S-CA group.
Effect of S-CA on angiogenesis inhabitation ( ± S).
| Group | n | Dose (μg/egg) | Large Vessels | Medium Vessels | Small Vessels |
|---|---|---|---|---|---|
| 13 | - | 8.92 ± 4.80 | 11.84 ± 3.33 | 11.6 ± 2.07 | |
| 13 | 20 | 12.4 ± 4.77 | 12.1 ± 3.92 | 4.16 ± 3.04 * | |
| 12 | 10 | 12.5 ± 6.94 | 10.33 ± 5.25 | 5.1 ± 1.22 * | |
| 12 | 40 | 12.6 ± 7.68 | 9.00 ± 4.44 | 3.5 ± 2.73 * |
* p < 0.05, large vessels (inner diameter > 100 μm), medium vessels (50 μm < inner diameter < 100 μm), small vessels (inner diameter < 50 μm).
Results of S-CA on mortality of acute toxicity test in mice.
| Group | Mice Number Start/End | Dose (mg/kg) | Death Rate (%) | LD50 (mg/kg) | 95% CIs |
|---|---|---|---|---|---|
| 10/10 | 10 | 10 | 25.624 | 13.04–50.34 | |
| 10/8 | 20 | 20 | |||
| 10/4 | 30 | 60 | |||
| 10/0 | 50 | 100 |
Antitumor Effects of S-CA in S180 Mice (Mean ± S.D.).
| Group | Dose (mg/kg) | Mice Number Start/End | Tumor Weight (g) | Inhibitory Rate (%) | Liver Index (100× g/g) | Spleen Index (mg/g) |
|---|---|---|---|---|---|---|
| - | 10/10 | - | - | 4.24 ± 0.54 | 4.27 ± 0.75 | |
| - | 10/10 | 0.684 ± 0.416 | - | 4.51 ± 0.53 | 5.25 ± 0.94 | |
| 20 | 10/10 | 0.249 ± 0.142 # | 63.52% | 4.98 ± 0.26 | 4.50 ± 1.39 | |
| 10 | 10/10 | 0.342 ± 0.291 # | 44.71% | 4.81 ± 0.32 | 6.33 ± 1.51 * |
* compared with normal group: * p < 0.05; # compared with model group: # p < 0.05.
Figure 3Histopathology of the mice bearing S180 xenografts after the treatment for 15 days. # compared with model group: # p < 0.05; ## compared with model group: ## p < 0.01. (a) Model group (400×). (b) Model group (100×). (c) CTX group (100×). (d) S-CA group (100×). (e) Tumor necrotic regions with HE staining of model and treatment groups of S180 mice.